BNP Paribas Financial Markets Purchases 41,541 Shares of Prothena Co. plc (NASDAQ:PRTA)

BNP Paribas Financial Markets lifted its holdings in Prothena Co. plc (NASDAQ:PRTA - Free Report) by 74.4% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 97,383 shares of the biotechnology company's stock after purchasing an additional 41,541 shares during the period. BNP Paribas Financial Markets owned about 0.18% of Prothena worth $1,349,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in PRTA. Hennion & Walsh Asset Management Inc. bought a new position in Prothena in the fourth quarter worth approximately $724,000. SG Americas Securities LLC raised its holdings in Prothena by 167.0% in the 4th quarter. SG Americas Securities LLC now owns 37,612 shares of the biotechnology company's stock worth $521,000 after purchasing an additional 23,525 shares during the period. Duncan Williams Asset Management LLC lifted its position in Prothena by 41.9% during the fourth quarter. Duncan Williams Asset Management LLC now owns 69,199 shares of the biotechnology company's stock valued at $958,000 after purchasing an additional 20,450 shares in the last quarter. Chicago Partners Investment Group LLC purchased a new position in Prothena during the fourth quarter valued at $159,000. Finally, China Universal Asset Management Co. Ltd. grew its holdings in Prothena by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,409 shares of the biotechnology company's stock valued at $158,000 after purchasing an additional 1,065 shares during the period. Hedge funds and other institutional investors own 97.08% of the company's stock.

Prothena Stock Performance

Shares of NASDAQ PRTA opened at $7.40 on Tuesday. The company has a market cap of $398.32 million, a P/E ratio of -3.22 and a beta of 0.11. Prothena Co. plc has a 52-week low of $6.47 and a 52-week high of $25.42. The firm's fifty day moving average is $10.21 and its two-hundred day moving average is $13.15.

Prothena (NASDAQ:PRTA - Get Free Report) last posted its earnings results on Thursday, May 8th. The biotechnology company reported ($1.12) EPS for the quarter, missing analysts' consensus estimates of ($0.92) by ($0.20). The firm had revenue of $2.83 million during the quarter, compared to analysts' expectations of $8.18 million. Prothena had a negative return on equity of 22.67% and a negative net margin of 90.50%. Prothena's quarterly revenue was up 5500.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.34) earnings per share. As a group, analysts forecast that Prothena Co. plc will post -4.04 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on PRTA. Piper Sandler raised their price objective on Prothena from $94.00 to $110.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 26th. Cantor Fitzgerald upgraded shares of Prothena to a "strong-buy" rating in a research report on Tuesday, May 13th. StockNews.com upgraded shares of Prothena from a "sell" rating to a "hold" rating in a research report on Monday, February 24th. Royal Bank of Canada lowered their target price on shares of Prothena from $24.00 to $20.00 and set a "sector perform" rating on the stock in a research note on Friday, February 21st. Finally, HC Wainwright cut their price target on Prothena from $48.00 to $30.00 and set a "buy" rating for the company in a research note on Friday, May 9th. Three equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, Prothena presently has a consensus rating of "Moderate Buy" and a consensus price target of $51.71.

About Prothena

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.